Mutual Funds Sahi Hai!
To avail the service, you will be redirected to loans.geojitcredits.com
The company has also received tentative approval for Dapagliflozin and Metformin Hydrochloride Extended-Release Tablets (2.5 mg/1,000 mg). The approved product is bioequivalent to Xigduo XR and will be used for the same indications as per the approved label.
Lupin is a global pharmaceutical leader headquartered in Mumbai, India, with products distributed in over 100 markets. It specializes in pharmaceutical products, including branded and generic formulations, complex generics, biotechnology products, and active pharmaceutical ingredients.
The pharmaceutical company reported a 37.46% surge in consolidated net profit to Rs 1,175.55 crore in Q3 FY26 as against Rs 855.16 crore posted in Q3 FY25. Total revenue from operations jumped 24.26% year-on-year to Rs 7,167.52 crore in the quarter ended 31 December 2025.
Shares of Lupin shed 0.35% to Rs 2,285.60 on the BSE.
The U.S. FDA has approved Lupin's Dapagliflozin and Metformin Hydrochloride Extended-Release Tablets as bioequivalent to Xigduo® XR for the indications in the approved labeling.
Lupin Ltd is down for a fifth straight session today. The stock is quoting at Rs 2255.6, down 0.83% on the day as on 13:19 IST on the NSE. The benchmark NIFTY is up around 0.67% on the day, quoting at 22864.2. The Sensex is at 73776.78, up 0.62%.Lupin Ltd has lost around 2.06% in last one month.Meanwhile, Nifty Pharma index of which Lupin Ltd is a constituent, has eased around 5.19% in last one month and is currently quoting at 21808.4, down 0.3% on the day. The volume in the stock stood at 4.95 lakh shares today, compared to the daily average of 10.47 lakh shares in last one month.
The benchmark April futures contract for the stock is quoting at Rs 2262.4, down 0.08% on the day. Lupin Ltd jumped 17.29% in last one year as compared to a 3.17% rally in NIFTY and a 8.74% spurt in the Nifty Pharma index.
The PE of the stock is 18.82 based on TTM earnings ending December 25.
The company said it will address the observations and respond to the US FDA within the stipulated timeframe. Lupin added that it remains committed to compliance with Current Good Manufacturing Practice (CGMP) standards across all its facilities.
Lupin has received the Establishment Inspection Report (EIR) from the United States Food and Drug Administration (US FDA) for its facility in Goa, India, with a satisfactory Voluntary Action Indicated (VAI) classification. The EIR was issued following an inspection of the facility from November 10 to November 21, 2025.
Nilesh Gupta, Managing Director, Lupin, stated, “We are pleased to have received the EIR with a VAI classification from the US FDA for our Goa facility. This outcome reflects our continued focus on quality excellence and regulatory compliance, reinforcing our commitment to delivering safe and effective medicines to patients worldwide.”
The EIR follows an inspection conducted at the site from 10 November to 21 November, 2025, confirming compliance with regulatory standards.
Nilesh Gupta, managing director (MD), Lupin, stated, “We are pleased to have received the EIR with a VAI classification from the US FDA for our Goa facility. This outcome reflects our continued focus on quality excellence and regulatory compliance, reinforcing our commitment to delivering safe and effective medicines to patients worldwide.”
Shares of Lupin shed 0.03% to currently trade at Rs 2,322.40 on the BSE.
Brivaracetam Oral Solution is bioequivalent to Briviact Oral Solution, 10 mg/mL, of UCB, Inc. and is indicated for the treatment of partial-onset seizures in patients aged one month and older.
Following the regulatory approval, the company has initiated the launch of Brivaracetam Oral Solution in the United States market.
According to IQVIA MAT data for December 2025, Brivaracetam Oral Solution (RLD Briviact) recorded estimated annual sales of $135 million in the US.
The approval strengthens Lupin’s portfolio in the central nervous system (CNS) segment and reinforces its presence in the US generics market.
The counter rose 0.48% to Rs 2,263.85 on the BSE.
Lupin has received approval from the U.S. FDA for its Abbreviated New Drug Application (ANDA) for Brivaracetam Oral Solution 10 mg/mL. Brivaracetam is the bioequivalent to Briviact® Oral Solution, 10 mg/mL, of UCB, Inc. and is indicated for the treatment of partial-onset seizures in patients 1 month of age and older.
Following the approval, the company initiated the launch of Brivaracetam Oral Solution in the United States.
Brivaracetam Oral Solution (RLD Briviact) had an estimated annual sale of USD 135 million in the U.S. (IQVIA MAT December 2025).
Lupin Ltd is up for a third straight session in a row. The stock is quoting at Rs 2286.5, up 1.61% on the day as on 12:49 IST on the NSE. The benchmark NIFTY is up around 0.17% on the day, quoting at 25467.85. The Sensex is at 82264.76, up 0.05%. Lupin Ltd has risen around 6.32% in last one month.
Meanwhile, Nifty Pharma index of which Lupin Ltd is a constituent, has risen around 5.38% in last one month and is currently quoting at 22632.05, up 1.45% on the day. The volume in the stock stood at 5.95 lakh shares today, compared to the daily average of 8.04 lakh shares in last one month.
The benchmark March futures contract for the stock is quoting at Rs 2302.7, up 1.91% on the day. Lupin Ltd is up 20.91% in last one year as compared to a 12.96% spurt in NIFTY and a 13.66% spurt in the Nifty Pharma index.
The PE of the stock is 18.61 based on TTM earnings ending December 25.